As a class, sodium–glucose transporter 2 inhibitors are novel drugs initially developed for glycemic control in patients with type 2 diabetes. [Cowie MR, et al. Nat Rev Cardiol. 2020;1a] Their primary ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
A recent study found that Sodium-glucose co-transporter 2 (SGLT2) inhibitors use in hypertrophic cardiomyopathy (HCM) ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Researchers from Juntendo University, Japan examine the molecular mechanisms underlying the senolytic or senescent cell removal effects of the the sodium glucose co-transporter 2 inhibitor and its ...
Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback